Kindra Shepard
Nurse Practitioner · Terre Haute, INNPI 1326535816
Payments from drug & device makers
Across 505 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$2K
- Sanofi$599
- Regeneron Healthcare Solutions, Inc.$560
- Actelion Pharmaceuticals US, Inc.$501
- plus $4K from 32 others
What the payments were for
- Food & beverage$11,47795%
- Education$6355%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 77 | $2,647 |
| GSK | 131 | $2,062 |
| Boehringer Ingelheim | 60 | $1,543 |
| Sanofi | 18 | $599 |
| Regeneron Healthcare Solutions, Inc. | 17 | $560 |
| Actelion Pharmaceuticals US, Inc. | 16 | $501 |
| Harmony Biosciences LLC | 19 | $444 |
| Jazz Pharmaceuticals Inc. | 13 | $427 |
| United Therapeutics Corporation | 16 | $339 |
| Axsome Therapeutics, Inc. | 13 | $315 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $305 |
| Grifols USA, LLC | 16 | $282 |
| Mylan Specialty L.p. | 14 | $263 |
| Paratek Pharmaceuticals, Inc. | 6 | $208 |
| Insmed, Inc. | 5 | $180 |
| Amgen | 9 | $175 |
| Mallinckrodt Hospital Products Inc. | 3 | $149 |
| Bayer | 2 | $137 |
| Merck | 6 | $113 |
| Vapotherm Inc | 1 | $110 |
| Philips North America LLC | 6 | $101 |
| Idorsia Pharmaceuticals US Inc | 5 | $84 |
| Teva Pharmaceuticals USA, Inc. | 5 | $69 |
| Baxter Healthcare | 2 | $58 |
| Electromed, Inc. | 7 | $50 |
| Novartis | 2 | $48 |
| Verona Pharma, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Genentech USA, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| Vifor Pharma, Inc. | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Viatris Specialty LLC | 1 | $29 |
| Pulmonx Corporation | 2 | $27 |
| Masimo Corporation | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| ZOLL Respicardia, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,112 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 171 | $678,447 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 730 | $672,263 |
| OfevNintedanib Esylate | 48 | $554,089 |
| Dupixent SyringeDupilumab | 55 | $236,350 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 202 | $150,411 |
| Spiriva RespimatTiotropium Bromide | 122 | $99,126 |
| Breo ElliptaFluticasone/Vilanterol | 160 | $78,473 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 112 | $73,494 |
| XolairOmalizumab | 16 | $54,295 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 82 | $45,651 |
| SymbicortBudesonide/Formoterol Fumarate | 117 | $41,643 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $36,647 |
| Spiriva HandihalerTiotropium Bromide | 26 | $23,968 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 740 | $20,438 |
| DuleraMometasone/Formoterol | 32 | $19,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,062 | $787,383957 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,543 | $772,359364 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,647 | $201,951339 claims |
| MerckDulera | $113 | $19,97732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Terre Haute
- Lindsay GambleTerre Haute$13K
- Lisa FergusonTerre Haute$11K
- Ashley McCammonTerre Haute$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.